RSV Vaccines and the Pharm Playbook

RSV Vaccines and the Pharm Playbook

Recently, there has been reporting of a surge in Respiratory Syncytial Virus (RSV) infections in children. Members of our Scientific and Medical Advisory Committee (SMAC) take a closer look at the virus, its risks, and attempts for creating a vaccine. They note that RSV alarmism follows “The Playbook” of a vaccine promotion campaign rather than one supporting the precautionary principle.

Related Posts

The Impact of Synthetic mRNA on Health

Professor Karina Acevedo-Whitehouse presented to the World Council For Health General Assembly on the topic of safety concerns with the components of the COVID-19 genetic vaccines.